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The Intra-aortic Balloon Pump (IABP) is currently the most
commonly used mechanical assist device to improve and support
hemodynamics in patients with cardiogenic shock; it is widely used
also in high-risk patients undergoing percutaneous coronary inter-
vention (PCI) or coronary artery bypass grafting (CABG) [1–9].
However, the impact of IABP on prognosis is so far controversial [5,10].
We assessed the in-hospital mortality and complications in
patients treated with IABP consecutively admitted to our Intensive
Cardiac Care Unit (ICCU).
From Jan. 1, 2005 to Dec. 31, 2008, 3500 patients were consecutively
admitted to our ICCU [11–13]. Among them, 414 (11.8%) underwent IABP
during their hospitalization and were prospectively enrolled in our
Registry.
Large ischemic risk area (LIRA)was defined as “ejection fraction less
than 40% together with proximal occlusion of left descending anterior
coronary artery associated or not with critical lesions in other
coronary arteries”. In these patients IABP was deployed after PCI.
Patients were defined as “high risk” as if one ormore of the following
criteria were present: ventricular ejection fraction (LVEF)<40%, killip
class 3, persistent malignant ventricular arrhythmias, acute mitral
regurgitation and severe coronary artery disease (left main stem or
three vessel or vein graft disease).
Major bleeding.Major bleeding was defined according to Replace 2
[14]:
Continuous data (Kolmogorov–Smirnov test ) were expressed as
mean±SD, categorical data as frequencies and percentages. All data
were analysed by means of Fisher's exact test or Student's t test, when
appropriate. Variables resulted significantly different between sub-
groups were entered as covariates in a backward stepwise logistic
regression analysis. A p<0.05 was considered statistical significant
(SPSS 13.0 statistical software; SPSS Inc., Chicago, ILL, USA).
The mean age of patients in the study was 68.5±11.4 years; 69.6%
were men. Hypertension was detectable in 51.4% (n=213), dyslipi-
demia in 32.1% (n=133) and diabetes mellitus in 22.0% (n=91).
About one fourth of patients (24.4%) showed prior myocardial
infarction and prior PCI in the 20.5%.
Table 1 shows indications for IABP in our series. In the majority of
patients (67.1%, n=278) IABP was the only device, while in the
remaining (32.9%) it was associated to other devices. The device most
frequently associated with IABP was mechanical ventilation (41.7%;
invasive: 24.6%; non-invasive 17.1%). The continuous veno-venous
renal replacement therapy was used in 13.5% (n=56) of patients.
Unfractioned heparin was used in 97.8% of patients. The majority of
patients received dual antiplatelet therapy; acetylsalicylic acid
(90.6%) and clopidogrel (83.8%). Therapy with glycoprotein IIb IIIa
inhibitors was administered in 59.7% of cases. Inotropic agents
(epinephrine, norepinephrine, dopamine and dobutamine) were
used in 40.6% of patients, all with refractory cardiogenic shock.
In our series, complications were 13.8% (57/414 patients) (Table 2).
Thirtypatients (outof 57, 52.7.%) showed severebleeding, amongwhich
half of patients exhibited unknown bleeding site while bleeding at the
insertion site occurred in 12 patients. The incidence of IABP-related
complications did not differ betweenmales and females (10.6%@versus
13.9% p=0.398). Patients who developed IABP-related complications
showed a higher median duration of the device (48 h; 25–75th
percentile 24–72 hversus 36 h;25–75thpercentile 24–48 h;p=0.007).
In our population, 82 patients died (82/414:19.8%). Among patients
who died, IABP was implanted because of: cardiogenic shock in 59
patients (72%), cardiac arrest in 8 patients (9.8%), periprocedural
complications of PCI in 5 patients (6.1%), mechanical complication of
acute myocardial infarction in 4 patients (4.9%), large ischemic risk area
in 3 patients (3.6%), acute pulmonary edema in 2 patients (2.4%) and
bridge to CABG in 1 patient (1.2%).
Among the 47 patientswhodeveloped IABP-related complications 22
died; two deaths were due to IABP (intestinal ischemia in 1 patients and
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Table 1
IABP indications.
Frequencies (%)
Diagnosis IABP indication
STEMI [latency<12 h]
(n=251 [60.6%])
Large ischemic risk area 86 (34.3)
Cardiogenic shock 73 (29.1)
Hypotension 38 (15.1)
Sudden death/VF 15 (6.0)
In the caht lab 4 (26.7)
Outside the cath lab 11 (73.3)
PCI failure 14 (5.6)
Acute pulmonary edema 11 (4.4)
Mechanical complications 10 (4.0)
Mitral regurgitation 6
VSD 4
Peri-procedural complications 2 (0.8)
Pre-operative support 2 (0.8)
STEMI [latency>12 h]
(n=38 [9.2%])
Cardiogenic shock 16 (42.1)
Large ischemic risk area 7 (18.4)
Mechanical complications 6 (15.8)
Mitral regurgitation 1
VSD 5
Hypotension 5 (13.2)
Acute pulmonary edema 3 (7.9)
Others 1
UA/NSTEMI
(n=109 [26.3%])
Severe coronary artery
disease in high-risk patients
28 (25.7)
Hypotension 20 (18.3)
Cardiogenic shock 16 (14.7)
Peri-procedural complications 15 (13.8)
Acute pulmonary edema 12 (11.0)
Pre-operative support 10 (9.2)
Sudden death/VF 8 (7.3)
In the caht lab 4
Outside the cath lab 4
CHD with CABG
indication (n=9 [2.2%])
Election procedure 3 (33.3)
Cardiogenic shock 3 (33.3)
Refractory angina 2 (22.2)
Peri-procedural complications 1 (11.1)
Pulmonary embolism
(n=5 [1.2%])
Other (n=2 [0.5%])
Cardiogenic shock 5 (100.0)
STEMI: ST elevation myocardial infarction; VF: ventricular fibrillation; PCI:
percutaneous coronary intervention; UA: unstable angina; NSTEMI: non ST elevation
myocardial infarction; VSD: ventricular septal defect; CHD: coronary heart disease.
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Table 2
IABP complications.
Complications (total) 57/414(13.8%)
Strictly related to IABP Severe bleeding 30 (52.7%)
Non specific site (acute anemia) 15 (50.0%)
Bleeding at the insertion site 12 (40.0%)
Retro-peritoneal hematoma 3 (10.0)
Limb ischemia 10 (17.5%)
Sistemic embolization (renal/mesenteric
infarct)
4 (7.0%)
Pseudo aneurysm of femoral artery 3 (5.3%)
Not strictly related to
IABP
Gastrointestinal and urinary bleeding 10 (17.5%)
severe bleeding associated with retroperitoneal hematoma in 1 patient).
In ourpopulationoverall strictly IABP-relatedmortalitywas0.5% (2/414).
At backward logistic regression analysis the following variableswere
independent predictors for in-ICCUmortality: killip class (OR 1.86; 95%
CI 1.41–2.46; p<0.001); age (OR 1.04; 95%CI 1.01–1.08; p=0.018);
aPTT max (OR 1.007; 95%CI 1.001–1.013; p=0.015); eGFR (OR 0.98;
95%CI 0.96–0.99; p=0.037) and admission glycemia (OR 2.07; 95%CI
1.39–3.07; p<0.001). Hosmer–Lemeshow test: 2.996; p=0.935.
At backward logistic regression analysis the following variables
resulted as independent predictor for IABP-related complications
(when adjusted for age and admission systolic blood pressure, and
IABP duration): aPTT max (OR 1.008; 95%CI 1.002–1.013; p=0.010);
admission glycemia (OR 1.68; 95%CI 1.21–2.34; p=0.002); minimum
platelet count (OR 0.991; 95%CI 0.985–0.997; p=0.005). Hosmer–
Lemeshow test: 8.23; p=0.412.
The main findings of our Registry are as follows: a) in our clinical
practice the most frequent indications for IABP implantation are not
included in guidelines; b) the incidence of “strictly IABP-related”
mortality and complications are low and c) clinicians should carefully
monitor anticoagulation, since aPTT max is an independent predictor
for IABP-related complications.
In our institution, the most frequent indication for IABP implanta-
tion is represented by large ischemic risk area in STEMI patients
treated with primary PCI. So far, this indication is supportedmainly by
experimental data [15,16]. In a randomized experimental study,
Azevedo et al. [16] demonstrated that IABP counterpulsation improves
the time course of recovery of LV systolic function after reperfused
AMI. Using both tagged and contrast enhanced magnetic resonance
imaging, the Authors demonstrated that this beneficial effect is mainly
due to an acceleration of the functional recovery of non-infarcted,
stunnedmyocardial regions. A series of 116 subjects at a single center,
following successful PCI for anterior AMI and total occlusion received
either conventional treatment or an IABP. Those subjectswhohad IABP
after successful PTCA had lower rates of reinfarction (0/48) with
respect to patientswithout IABP 1/42 [17]. In our investigation, though
our study design does not allowus to drawany conclusions in regard to
benefits (since the lack of randomization), IABP implantation in
patients with large ischemic risk area is safe since the incidence of
complications in this subgroup is low as well as its mortality.
The most frequent and feared complication is represented by
major bleeding and aPTT max resulted an independent predictor for
IABP-related complications, thus underlining the importance of a
close monitoring of anticoagulation in these patients.
In our series, the incidence of IABP-related complications is higher
than that reported in the Benchmark Registry [3], mainly because of
the different definitions of severe bleeding and different inclusion
criteria for complication. [18–20].
In our daily current practice, indications for IABP implantation are
not strictly those reported in guidelines. However IABP can be
considered a safe device because of the low incidence of IABP-related
complications and mortality.
The authors of this manuscript have certified that they comply
with the Principles of Ethical Publishing in the International Journal of
Cardiology [21].
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